The significance of a B cell-dependent immunopathology in multiple sclerosis;Die Relevanz einer B-Zell-abhängigen Immunpathologie für die Multiple Sklerose

Fortschritte der Neurologie Psychiatrie

Volumn 79, Issue 2, 2011, Pages 83-91

  Kuerten, S ^a   Pauly, R ^a   Blaschke, S ^a   Rottlaender, A ^a   Kaiser, C C ^b   Schroeter, M ^b   Fink, G R ^b   Addicks, K ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

antibodies; autoimmunity; B cells; EAE; MS

Indexed keywords

AUTOANTIBODY;

ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; CENTRAL NERVOUS SYSTEM; CLINICAL ASSESSMENT; DISEASE COURSE; DISEASE SEVERITY; IMMUNOPATHOLOGY; MULTIPLE SCLEROSIS;

ANIMALS; ANTIGEN-PRESENTING CELLS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; CELL AGGREGATION; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY; MULTIPLE SCLEROSIS;

EID: 79751524893     PISSN: 07204299     EISSN: 14393522     Source Type: Journal    
DOI: 10.1055/s-0029-1245937     Document Type: Article

References (96)

1. Batoulis H, Addicks K, Kuerten S. Emerging concepts in autoimmune encephalomyelitis beyond the CD 4 /T(H)1 paradigm. Ann Anat 2010 192 179-193
2. Lassmann H, Ransohoff R M. The CD 4-Th1 model for multiple sclerosis: a (Pubitemid 38249486)
3. Awad A, Hemmer B, Hartung H P. et al. Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis. J Neuroimmunol 2010 219 1-7
4. Luque F A., Jaffe S L. Cerebrospinal fluid analysis in multiple sclerosis. Int Rev Neurobiol 2007 79 341-56
5. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005 23 683-747 (Pubitemid 40563183)
6. Franciotta D, Salvetti M, Lolli F et al. B cells and multiple sclerosis. Lancet Neurol 2008 7 852-858
7. Bielekova B, Becker B. Monoclonal antibodies in MS - Mechanisms of action. Neurology 2010 74 (Suppl 1) S31-S40
8. Owens G P., Bennett J L., Lassmann H et al. Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid. Ann Neurol 2009 65 639-649
9. Reindl M, Linington C, Brehm U et al. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study. Brain 1999 122 2047-2056
10. Reindl M, Khalil M, Berger T. Antibodies as biological markers for pathophysiological processes in MS. J Neuroimmunol 2006 180 50-62 (Pubitemid 44692320)
11. Büdingen H C., Harrer M D., Kuenzle S von et al. Clonally expanded plasma cells in the cerebrospinal fluid of MS patients produce myelin-specific antibodies. Eur J Immunol 2008 38 2014-2023
12. Büdingen H C., Gulati M von, Kuenzle S et al. Clonally expanded plasma cells in the cerebrospinal fluid of patients with central nervous system autoimmune demyelination produce oligoclonal bands. J Neuroimmunol 2010 218 134-139
13. Magliozzi R, Howell O, Vora A et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007 130 1089-1104 (Pubitemid 47355604)
14. Keegan M, König F, McClelland R et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 2005 366 579-582 (Pubitemid 41140333)
15. Hauser S L., Waubant E, Arnold D L. et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008 358 676-688 (Pubitemid 351240747)
16. Schröder A, Ellrichmann G, Chehab G et al. Einsatz von Rituximab in der Behandlung neuroimmunologischer Erkrankungen. Nervenarzt 2009 80 155-165
17. Buttmann M. Treating multiple sclerosis with monoclonal antibodies: a 2010 update. Expert Rev Neurother 2010 10 791-809
18. Rivers T M., Schwentker F F. Encephalomyelitis accompanied by myelin destruction experimentally produced in monkeys. J Exp Med 1935 61 689-702
19. Kabat E A., Moore D H., Landow H. An electrophoretic study of the protein components in cerebrospinal fluid and the relationship to the serum proteins. J Clin Invest 1942 21 571-577
20. Link H, Baig S, Jiang Y P. et al. B cells and antibodies in MS. Res Immunol 1989 140 219-226 (Pubitemid 19121168)
21. Bernard C C., Rosbo N K. Immunopathological recognition of autoantigens in multiple sclerosis. Acta Neurol 1991 13 171-178
22. Menon K de, Piddlesden S J., Bernard C C. Demyelinating antibodies to myelin oligodendrocyte glycoprotein and galactocerebroside induce degradation of myelin basic protein in isolated human myelin. J Neurochem 1997 69 214-222 (Pubitemid 27274175)
23. Van der Goes A, Kortekaas M, Hoekstra K et al. The role of anti-myelin (auto)-antibodies in the phagocytosis of myelin by macrophages. J Neuroimmunol 1999 101 61-67 (Pubitemid 29505174)
24. Ponomarenko N A., Durova O M., Vorobiev I I. et al. Autoantibodies to myelin basic protein catalyze site-specific degradation of their antigen. Proc Natl Acad Sci U S A 2006 103 281-286 (Pubitemid 43122392)
25. Karthigasan J, Garvey J S., Ramamurthy G V. et al. Immunolocalization of 17 and 21.5 kDa MBP isoforms in compact myelin and radial component. J Neurocytol 1996 25 1-7
26. Wucherpfennig K W. Autoimmunity in the central nervous system: mechanisms of antigen presentation and recognition. Clin Immunol Immunopathol 1994 72 293-306 (Pubitemid 24275207)
27. Yamamoto Y, Yoshikawa H, Nagano S et al. Myelin-associated oligodendrocytic basic protein is essential for normal arrangement of the radial component in central nervous system myelin. Eur J Neurosci 1998 11 847-855 (Pubitemid 29106045)
28. Lehmann P V., Forsthuber T, Miller A et al. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 1992 358 155-157
29. Popot J L., Pham Dinh D, Dautigny A. Major Myelin proteolipid: the 4-alpha-helix topology. J Membr Biol 1991 120 233-246
30. Schliess F, Stoffel W. Evolution of the myelin integral membrane proteins of the central nervous system. Biol Chem Hoppe Seyler 1991 372 865-874
31. Tumani H, Hartung H P., Hemmer B et al. Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol Dis 2009 35 117-127
32. Ehling R, Lutterotti A, Wanschitz J et al. Increased frequencies of serum antibodies to neurofilament light in patients with primary chronic progressive multiple sclerosis. Mult Scler 2004 10 601-606 (Pubitemid 39585235)
33. Silber E, Semra Y K., Gregson N A. et al. Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit. Neurology 2002 58 1372-1381 (Pubitemid 34507164)
34. Sadatipour B T., Greer J M., Pender M P. Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis. Ann Neurol 1998 44 980-983 (Pubitemid 28558264)
35. Banki K, Colombo E, Sia F et al. Oligodendrocyte-specific expression and autoantigenicity of transaldolase in multiple sclerosis. J Exp Med 1994 180 1649-1663 (Pubitemid 24328557)
36. Mathey E K., Derfuss T, Storch M K. et al. Neurofascin as novel target for antibody mediated axonal injury. J Exp Med 2007 204 2363-2372 (Pubitemid 47529322)
37. Menge T, Lalive P H., Budingen H C. et al. Antibody responses against galactocerebroside are potential stage-specific biomarkers in multiple sclerosis. J Allergy Clin Immunol 2005 116 453-459 (Pubitemid 41096558)
38. Villar L M., Sadaba M C., Roldan E von et al. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J Clin Invest 2005 115 187-194 (Pubitemid 40385520)
39. Silber E, Semra Y K., Gregson N A. et al. Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit. Neurology 2002 58 1372-1381 (Pubitemid 34507164)
40. Eikelenboom M J., Petzold A, Lazeron R H. et al. Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy. Neurology 2003 60 219-223 (Pubitemid 36152012)
41. Sidén A. Isoelectric focusing and crossed immunoelectrofocusing of CSF immunoglobulins in MS. J Neurol 1979 221 39-51 (Pubitemid 9245037)
42. Link H, Huang Y M. Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness. J Neuroimmunol 2007 180 17-28
43. Vaheri A, Keski-Oja J, Salonen E M. et al. Cerebrospinal fluid IgG bands and virus-specific IgG, IgM, and IgA antibodies in herpes simplex virus encephalitis. J Neuroimmunol 1982 3 247-261 (Pubitemid 13151359)
44. Stanek G. Laboratory diagnosis and seroepidemiology of Lyme borreliosis. Infection 1991 19 263-267
45. Ceroni M, Camana C, Franciotta D M. et al. Specific activation of B-cell clones within the central nervous system in course of herpes simplex encephalitis. Boll Soc Ital Biol Sper 1990 66 1223-1230
46. Shen X, Tan Y. Detection of oligoclonal immunoglobulins in the cerebrospinal fluid by immunofixation electrophoresis. Clin Chem Lab Med 2001 39 1209-1210 (Pubitemid 34026560)
47. Dornmair K, Meinl E, Hohlfeld R. Novel approaches for identifying target antigens of autoreactive human B and T cells. Semin Immunopathol 2009 31 467-477
48. Lucchinetti C, Brück W, Parisi J et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000 47 707-717 (Pubitemid 30390191)
49. Qin Y, Duquette P, Zhang Y et al. Intrathecal B-cell clonal expansion, an early sign of humoral immunity, in the cerebrospinal fluid of patients with clinically isolated syndrome suggestive of multiple sclerosis. Lab Invest 2003 83 1081-1088 (Pubitemid 36899074)
50. Rock K L., Benacerraf B, Abbas A K. Antigen presentation by hapten-specific B lymphocytes. I. Role of surface immunoglobulin receptors. J Exp Med 1984 160 1102-1113 (Pubitemid 14020970)
51. Constant S L. B lymphocytes as antigen-presenting cells for CD 4 T cell priming in vivo. J Immunol 1999 162 5695-5703 (Pubitemid 29314919)
52. Greter M, Heppner F L., Lemos M P. et al. Dendritic cells permit immune invasion of the CNS in animal model of multiple sclerosis. Nat Med 2005 11 328-334 (Pubitemid 40460562)
53. Racke M. The role of B cells in multiple sclerosis: rationale for B-cell-targeted therapies. Curr Opin Neurol 2008 21 (Suppl 1) S9-S18 (Pubitemid 351483538)
54. Harp C T., Lovett-Racke A E., Racke M K. et al. Impact of myelin-specific antigen presenting B cells on T cell activation in multiple sclerosis. Clin Immunol 2008 128 382-391
55. Serafini B, Rosicarelli B, Magliozzi R et al. Detection of ectopic B-cell follicles with germinal centers in meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004 14 164-174 (Pubitemid 38656388)
56. Aloisi F, Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol 2006 6 205-217 (Pubitemid 43290990)
57. Kaiser C C., Shukla D K., Stebbins G T. et al. A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis. J Neuroimmunol 2009 211 124-130
58. Serafini B, Severa M, Columba-Cabezas S et al. Epstein-Barr virus latent i nfection and BAFF expression in B cells in the multiple sclerosis brain: implications for viral persistence and intrathecal B-cell activation. J Neuropathol Exp Neurol 2010 69 677-693
59. Bø L, Vedeler C A., Nyland H et al. Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult Scler 2003 9 323-331 (Pubitemid 36958014)
60. Willis S N., Stadelmann C, Rodig S J. et al. Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain 2009 132 3318-3328
61. Sargsyan S A., Shearer A J., Ritchie A M. et al. Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis. Neurology 2010 74 1127-1135
62. Fillatreau S, Sweenie C H., McGeachy M J. et al. B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002 3 944-950 (Pubitemid 35154008)
63. Matsushita T, Yanaba K, Bouaziz J D. et al. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest 2008 118 3420-3430
64. Warrington A E., Asakura K, Bieber A J. et al. Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis. Proc Natl Acad Sci USA 2000 97 6820-6825 (Pubitemid 30412798)
65. Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006 129 1953-1971 (Pubitemid 44289062)
66. Goverman J, Brabb T. Rodent models of experimental allergic encephalomyelitis applied to the study of multiple sclerosis. Lab Anim Sci 1996 46 482-492
67. Kuerten S, Angelov D N. Comparing the CNS morphology and immunobiology of different EAE models in C 57BL/ 6 mice - a step towards understanding the complexity of multiple sclerosis. Ann Anat 2008 190 1-15
68. Steinmann L, Zamvil S. Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. Trends in Immunol 2005 26 565-571 (Pubitemid 41726443)
69. Steinman L, Zamvil S S. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann Neurol 2006 60 12-21
70. Yip H C., Karulin A Y., Tary-Lehmann M et al. Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response. J Immunol 1999 162 3942-3949 (Pubitemid 29314773)
71. Sriram S, Steiner I. Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis. Ann Neurol 2005 58 939-945 (Pubitemid 41746884)
72. Stefferl A, Storch M K., Linington C et al. Disease progression in chronic relapsing experimental allergic encephalomyelitis is associated with reduced inflammation-driven production of corticosterone. Endocrinology 2001 142 3616-3612
73. Genain C P., Nguyen M H., Letvin N L. et al. Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate. J Clin Invest 1995 96 2966-2974
74. 't Hart B A., Massacesi L. Clinical, pathological, and immunologic aspects of the multiple sclerosis model in common marmosets (Callithrix jacchus). J Neuropathol Exp Neurol 2009 68 341-355
75. Hjelmstrom P, Juedes A E., Fjell J et al. B-cell-deficient mice develop experimental allergic encephalomyelitis with demyelination after myelin oligodendrocyte glycoprotein sensitization. J Immunol 1998 161 4480-4483 (Pubitemid 28492015)
76. Oliver A R., Lyon G M., Ruddle N H. Rat and human myelin oligodendrocyte glycoproteins induce experimental autoimmune encephalomyelitis by different mechanisms in C 57BL/ 6 mice. J Immunol 2003 171 462-468 (Pubitemid 36745321)
77. Kuerten S, Lichtenegger F S., Faas S et al. MBP-PLP fusion protein-induced EAE in C 57BL/ 6 mice. J Neuroimmunol 2006 177 99-111 (Pubitemid 44131573)
78. Kuerten S, Javeri S, Tary-Lehmann M et al. Fundamental differences in the CNS lesion development and composition in MP 4- and MOG:35 - 55-induced EAE. Clin Immunol 2008 129 256-267
79. Elliott E A., McFarland H I., Nye S H. et al. Treatment of experimental encephalomyelitis with a novel chimeric fusion protein of myelin basic protein and proteolipid protein. J Clin Invest 1996 98 1602-1612 (Pubitemid 26327870)
80. Pöllinger B, Krishnamoorthy G, Berer K et al. Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells. J Exp Med 2009 206 1303-1316
81. Genc K, Dona D L., Reder A T. Increased CD 80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy. J Clin Invest 1997 99 2664-2671 (Pubitemid 27259813)
82. Kim H J., Ifergan I, Antel J P. et al. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Immunol 2004 172 7144-7153 (Pubitemid 38669158)
83. Kala M, Rhodes S N., Piao W H. et al. B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis. Exp Neurol 2010 221 136-145
84. Begum-Haque S, Sharma A, Christy M et al. Increased expression of B-cell associated regulatory cytokines by glatiramer acetate in mice with experimental autoimmune encephalomyelitis. J Neuroimmunol 2010 219 47-53
85. Krumbholz M, Faber H, Steinmeyer F et al. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain 2008 131 1455-1463 (Pubitemid 351806460)
86. Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat Rev Drug Discov 2005 4 510-518 (Pubitemid 40861993)
87. Rudick R A., Sandrock A. Natalizumab. alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev Neurother 2004 4 571-580 (Pubitemid 38890585)
88. Krumbholz M, Meinl I, Kümpfel T et al. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology 2008 71 1350-1354
89. Weissert R. Progressive multifocal leukoencephalopathy. J Neuroimmunol 9 Oct 2010 [Epub ahead of print]
90. Meinl E, Krumbholz M, Hohlfeld R. B linage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production and therapeutic modulation. Ann Neurol 2006 59 880-892 (Pubitemid 43830920)
91. Menge T, Büdingen H C., Dalakas M C. et al. B-Zell-gerichtete Multiple-Sklerose-Therapie: Aktueller Stand. Nervenarzt 2009 80 190-198
92. Cross A H., Stark J L., Lauber J et al. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 2006 180 63-70 (Pubitemid 44767709)
93. Nückel H, Frey U H., Röth A et al. Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity. Eur J Pharmacol 2005 514 217-224 (Pubitemid 40723643)
94. Hawker K. B-cell-targeted treatment for multiple sclerosis: mechanism of action and clinical data. Curr Opin Neurol 2008 21 (Suppl 1) S19-S25 (Pubitemid 351483539)
95. Monson N. The natural history of B cells. Curr Opin Neurol 2008 21 (Suppl 1) S3-S8 (Pubitemid 351483537)
96. (Pubitemid 40066141)